Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage live biotherapeutics company that regularly issues news about its microbiome-based drug programs, regulatory interactions, and corporate developments. The company focuses on oral live biotherapeutics for medically vulnerable patient populations, particularly adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) and other high-risk groups.
News about Seres often centers on its lead investigational candidate SER-155, including Phase 1b clinical data showing a significant reduction in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia in allo-HSCT patients compared with placebo. Updates also cover regulatory designations for SER-155, such as Breakthrough Therapy and Fast Track status, and detailed feedback from the U.S. Food and Drug Administration on the design of a planned Phase 2 study.
Investors and followers of MCRB can expect announcements on clinical trial progress, investigator-sponsored studies in areas like immune checkpoint inhibitor–related enterocolitis, and research presentations at major medical meetings. Seres also issues press releases on mechanistic publications for its live biotherapeutics, including VOWST™, and on data generated from its MbTx® platform that support its broader live biotherapeutic strategy.
In addition to R&D updates, Seres publishes news on cost-reduction actions, cash runway expectations, leadership changes, and efforts to secure capital or partnerships to advance its pipeline. For those tracking MCRB, this news feed provides a centralized view of program milestones, scientific data, regulatory interactions, and corporate actions that shape the company’s live biotherapeutics portfolio.
Seres Therapeutics (NASDAQ:MCRB) announced a significant leadership transition as Thomas DesRosier and Marella Thorell are appointed co-CEOs, effective July 31, 2025, following current CEO Eric Shaff's departure. Both executives will retain their existing roles as Chief Legal Officer and Chief Financial Officer, respectively.
The company is actively engaging with multiple parties for potential business development and partnerships to secure additional capital for advancing SER-155, which has received Breakthrough Therapy designation. The drug showed promising Phase 1b results with a 77% relative risk reduction in bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT).
Eric Shaff, who led Seres for a decade and achieved the first-ever FDA-approved oral microbiome therapy, will remain on the company's Board of Directors.
Seres Therapeutics (NASDAQ: MCRB) reported Q1 2025 financial results and provided updates on its lead candidate SER-155. The company plans to submit a Phase 2 study protocol to FDA for SER-155, targeting the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant. Previous Phase 1b data showed a 77% relative risk reduction in bloodstream infections.
Financial highlights include net income of $32.7 million for Q1 2025, compared to a net loss of $32.9 million in Q1 2024. The company had $58.8 million in cash as of March 31, 2025, with runway into Q1 2026. A $25 million payment from Nestlé is expected in July 2025. The company recently completed a 1-for-20 reverse stock split and regained Nasdaq compliance.
Seres Therapeutics announced three poster presentations at the upcoming 2025 Digestive Disease Week (DDW) Conference in San Diego. The company will showcase new research on live biotherapeutics for treating inflammatory and immune diseases, including ulcerative colitis and Crohn's disease.
The presentations include two new research posters focusing on:
- Characterization of IBD microbiomes to evaluate candidate biomarkers
- Biomarkers of microbiome disruption for patient selection in UC trials
A third poster will present previously disclosed results from the SER-155 Phase 1b study, which demonstrated positive outcomes in promoting intestinal barrier integrity and modulating inflammatory responses. Seres is actively seeking partnerships to advance their biotherapeutics development in inflammatory and immune diseases.
Seres Therapeutics (Nasdaq: MCRB), a leading live biotherapeutics company, has scheduled a conference call and live audio webcast for May 7, 2025, at 8:30 a.m. ET to discuss their first quarter 2025 financial results and provide business updates.
Investors can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 4618787. The webcast will be available in the 'Investors and News' section of the Seres website and will remain archived for approximately 21 days after the event.
Seres Therapeutics (MCRB) reported its Q4 and full year 2024 financial results, highlighting significant progress with SER-155, their live biotherapeutic candidate for preventing bloodstream infections in allogeneic hematopoietic stem cell transplant recipients.
Key developments include:
- SER-155 showed a 77% relative risk reduction in bloodstream infections in Phase 1b study
- FDA granted Breakthrough Therapy designation in December 2024
- Company plans to submit draft protocol for next study to FDA in Q2 2025
- Recent FDA feedback supports bloodstream infection reduction at day 30 post-HSCT as primary endpoint
Financial highlights: Net loss from continuing operations was $125.8M for 2024, compared to $190.1M in 2023. Cash position of $30.8M as of December 31, 2024, with expected funding into Q1 2026, including anticipated Nestlé payments.
Seres Therapeutics (MCRB) has scheduled a conference call and live audio webcast for March 13, 2025, at 8:30 a.m. ET to discuss their fourth quarter and full year 2024 financial results along with business updates. Interested participants can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) using conference ID 6331602. The webcast will be available in the Investors and News section of the Seres website, with a replay accessible approximately two hours after the event and archived for about 21 days.
Seres Therapeutics (MCRB) has received FDA feedback on its SER-155 development strategy for allogeneic hematopoietic stem cell transplant (allo-HSCT) patients. The FDA supported using reduction in bloodstream infections at 30 days post-HSCT as the primary endpoint for the next study, recommending it be a Phase 2 trial.
The company is considering either a Phase 2 or a Phase 2/3 design for operational efficiency and plans to submit the protocol to FDA in Q2 2024. The upcoming study will build on the successful Phase 1b Cohort 2 trial, which demonstrated a 77% relative risk reduction in bloodstream infections, reduced systemic antibiotic exposure, and lower febrile neutropenia incidence.
Seres is actively seeking a development partner for SER-155 in allo-HSCT and awaits additional FDA feedback on submitted clarification questions.
Seres Therapeutics (MCRB) has received a $50 million installment payment from Nestlé Health Science, related to the previously announced sale of its VOWST business. This payment was received as planned, with Seres meeting its transition obligations. The company anticipates an additional $25 million installment payment (less approximately $1.5M in employment-related payments) from Nestlé Health Science in July 2025. Based on current cash position, including these payments and considering transaction-related obligations and operating plans, Seres expects to maintain operational funding into the first quarter of 2026.
Seres Therapeutics (MCRB) announced new biomarker results from its SER-155 Phase 1b study in allogenic stem cell transplantation patients. The data showed statistically significant improvements in epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo, supporting the previously reported 77% reduction in bloodstream infections.
The company received FDA Breakthrough Therapy designation for SER-155 in December 2024 and expects agency feedback on its next registrational study this quarter. Market research with healthcare professionals and payers confirmed high unmet need and strong value proposition for SER-155 in preventing bloodstream infections.
Financially, Seres had approximately $31 million in cash as of December 31, 2024, and expects to receive about $75 million in installment payments from Nestlé Health Science in 2025. The company projects its cash runway to extend into Q1 2026 and is actively seeking partnerships to advance SER-155 development.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
